



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2013
12 August 2013

The General Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

The General Manager
Bombay Stock Exchange Limited.
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai

Sub: Un-audited Financial Results

Dear Sir,

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith copy of the Un-audited Financial Results and Segment Report for the quarter ended 30 June 2013 alongwith the Limited Review Certificate of the Statutory Auditor.

This is for your information and record please.

Thanking you

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited



[Krishan Singla]
Vice President & Company Secretary

- Encl : 1. Un-audited Financial Results & Segment Report
2. Limited review certificate

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works: Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India
Ph. : +91-1679 -285285-88, Fax : +91-1679-235292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2013

Rs. in Lacs

Sr. No.	Particulars	Quarter ended			Year ended
		(unaudited)	(unaudited)	(unaudited)	(Audited)
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
1	a Net Sales / Income from operations	13,914.34	13,549.40	12,476.56	48,151.10
	b Other Operating Income	90.27	41.58	172.98	251.09
	Total (1)	14,004.61	13,590.98	12,649.54	48,402.19
2	Expenditure				
	a Consumption of Raw Materials	9,243.66	9,246.57	7,768.71	33,168.34
	b Purchase of Traded Goods	0.00	30.00	3.64	234.86
	c (Increase) / Decrease in stock in trade and work in progress	74.48	(319.85)	132.88	(3,405.40)
	d Employees Cost	650.24	549.61	548.15	2,207.69
	e Depreciation	784.57	769.47	781.71	3,137.41
	f Other expenditure	1,591.19	1,886.16	1,871.26	7,041.27
	Total (2)	12,344.14	12,161.96	11,106.35	42,384.17
3	Profit from Operations before Other Income,	1,660.47	1,429.02	1,543.19	6,018.02
4	Other Income	0.45	0.45	0.45	1.80
5	Profit before Interest and Exceptional Items (3+4)	1,660.92	1,429.47	1,543.64	6,019.82
6	Interest	1,535.37	1,380.19	1,440.79	5,723.98
7	Profit after Interest but before Exceptional Items (5-6)	125.55	49.28	102.85	295.84
8	Exceptional Items	0.00			0.00
9	Profit (+) / Loss (-) from ordinary activities	125.55	49.28	102.85	295.84
10	Tax Expenses	43.06	42.56	34.00	136.98
11	Net Profit (+)/Loss (-) from ordinary activities after tax (9-10)	82.49	6.72	68.85	158.86
12	Extraordinary Item (net of tax expense)				
13	Net Profit (+)/Loss (-) for the period (11-12)	82.49	6.72	68.85	158.86
14	Paid-up equity share capital (Face value Rs.10/- Per Share)	2,615.12	2,615.12	2,615.12	2,615.12
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				14,184.34
16	Earning per share (weighted)				
	Basic	0.32	0.03	0.26	0.61
	Diluted	0.32	0.03	0.26	0.61
	Cash	3.38	3.09	3.32	12.81



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India

Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com

Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India

Ph. : +91-1679 -285285-88, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

PART-II SELECT INFORMATION FOR THE QUARTER ENDED 30 JUNE 2013

Sr. No.	Particulars	Quarter ended			Year ended
		(unaudited) 30.06.2013	(unaudited) 31.03.2013	(unaudited) 30.06.2012	(Audited) 31.03.2013
A	Particulars of Shareholding				
1	Public Shareholding				
	-- No of Shares	1,17,76,611	1,17,76,611	1,17,76,611	1,17,76,611
	%	45.03	45.03	45.03	45.03
2	Promoters and promoter group				
	Shareholding				
	a) Pledged/Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (% of the total shareholding of promoters)	-	-	-	-
	- Percentage of shares (% of the total shareholding)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	1,43,74,553	1,43,74,553	1,43,74,553	1,39,40,053
	- Percentage of shares (% of the total shareholding of promoters)	100.00	100.00	100.00	100.00
	- Percentage of shares (% of the total shareholding)	54.97	54.97	54.97	53.31

B	Particulars	3 Months Ended 30 June 2013	
	Investor Complaints		
1	Pending at the beginning of the quarter		NIL
2	Received during the quarter		NIL
3	Disposed of during the quarter		NIL
4	Remaining unresolved at the end of the quarter		NIL



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India

Ph. : +91-161-2225531-35 Fax : +91-161-2226429, 2608784 email : contact@iolep.com Website : iolep.com

Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India

Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India

Ph. : +91-1679 -285285-88, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement

Rs. in Lacs

Particulars	Quarter Ended			Year Ended
	unaudited	unaudited	unaudited	Audited
	30.06.2013	31.03.2013	30.06.2012	31.03.2013
1. Segment Revenue				
(Net sale/income)				
- Chemicals	8,844.70	8,931.97	8,170.05	30,467.86
- Drugs	7,011.36	6,642.83	5,946.42	24,749.77
- Unallocated	69.23	27.97	138.97	201.54
Total	15,925.29	15,602.77	14,255.44	55,419.17
Less : Inter segment transfer	1,920.68	2,011.79	1,605.88	7,016.98
Net sales/income from operations	14,004.61	13,590.98	12,649.56	48,402.19
2. Segment Results				
Profit(+)/(loss)(-) before tax and interest				
from each segment)				
- Chemicals	(111.57)	(180.00)	110.26	(606.95)
- Drugs	1,709.18	1,621.83	1,319.02	6,719.23
Total	1,597.61	1,441.83	1,429.28	6,112.28
Less: Interest	1,535.38	1,380.20	1,440.79	5,723.99
Less: Other un-allocable expenditure net of unallocable income	(63.32)	12.35	(114.36)	92.45
Total Profit(+)/(loss) (-) before tax & Extraordinary items	125.55	49.28	102.85	295.84
3. Capital Employed				
(Segment assets - Segment Liabilities)				
- Chemicals	5,748.01	7,266.09	8,605.57	7,266.09
- Drugs	10,548.66	9,121.49	8,167.42	9,121.49
- Unallocated including capital work in progress	1,001.03	911.87	656.13	911.87
Total	17,297.70	17,299.45	17,429.12	17,299.45

NOTES:

- The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of the Directors at their meeting held on 12 August 2013.
- Previous period's figures have been regrouped/ reclassified wherever necessary.
- Limited review of the above unaudited financial results of the Company in term of Clause 41 of the Listing Agreement has been carried out by the Statutory Auditors of the Company

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited



Vijay Kumar Garg
Joint Managing Director

Place: Ludhiana
Date: 12 August 2013

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India
Ph. : +91-1679 -285285-88, Fax : +91-1679-285292

REVIEW REPORT

To
The Board of Directors,
IOL Chemicals and Pharmaceuticals Ltd.
Ludhiana


1. We have reviewed the accompanying statement of unaudited financial results of IOL Chemicals and Pharmaceuticals Ltd. for the period ended 30th June, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial information based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable accounting standards referred to in sub clause (3C) of section 211 of the Companies Act, 1956 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed or that it contains any material misstatement.

Place: Ludhiana
Dated: 12 Aug, 2013

CERTIFIED TO BE TRUE COPY

For IOL Chemicals and Pharmaceuticals Limited

Krishan Singla
Vice President & Company Secretary

For S.C. VASUDEVA & Co.
Chartered Accountants
Firm reg. no. 000235N

(SANJIV MOHAN)
Partner
M. No 86066